(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 9.94% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ani Pharmaceuticals's revenue in 2025 is $674,068,000.On average, 1 Wall Street analysts forecast ANIP's revenue for 2025 to be $16,673,191,370, with the lowest ANIP revenue forecast at $16,673,191,370, and the highest ANIP revenue forecast at $16,673,191,370. On average, 7 Wall Street analysts forecast ANIP's revenue for 2026 to be $18,316,552,406, with the lowest ANIP revenue forecast at $17,745,673,771, and the highest ANIP revenue forecast at $19,097,161,896.
In 2027, ANIP is forecast to generate $19,402,335,236 in revenue, with the lowest revenue forecast at $18,364,988,493 and the highest revenue forecast at $20,643,824,055.